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From past to future in cardiovascular care and
research in Ticino
Moccetti Tiziano
Cardiocentro Ticino, Switzerland
In this article based on the Grüntzig Lecture 2018 the au-
thor gives his personal memories and a review of the de-
velopment of cardiology in the canton of Ticino.
Introduction
I cannot describe cardiovascular care and research in Tici-
no without mentioning my personal professional life, since
in the last 40 years I was one of the leaders in the progres-
sion of cardiology in this Canton.
I can divide my professional career into three periods:
in Zurich as medical doctor (the Zurich experience), in
Lugano as chief of Medicine at Ospedale Civico (the Os-
pedale Civico experience) and in Lugano as chief of Cardi-
ology at the Fondazione Cardiocentro Ticino (the Cardio-
centro experience) (fig. 1).
The Zurich experience (1963–1971)
In 1963, I obtained my medical degree at the University of
Zurich (my Alma mater). Then I started a 2-year fellow-
ship at the Pathologisches Institut at Zurich University. I
always will remember my mentors in anatomy and pathol-
ogy – Gian Töndury and Erwin Uehlinger. Over this time,
I had the unique experience of precisely determining the
cause of death in hundreds of autopsies. That experience
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Figure 1: Medical Institutions of my professional life.
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had a great impact in my professional life: I learned to be
always critical in the evaluation of complex cases. Certain-
ly, at that time I didn’t predict the extraordinary impact
on diagnostic workflow of modern noninvasive imaging
techniques, such echocardiography, computed tomography
(CT) and cardiac magnetic resonance imaging (CMR).
Nowadays, these techniques have greatly reduced the need
for autopsies in hospitals. It was during my training at the
institute of pathology that, for the first time, I took my first
steps toward the field of cardiology, writing my doctoral
thesis on the increase in the prevalence of coronary scle-
rosis in the years between the Second World War and the
prosperous 1960s [1].
This period was also the “Golden Age” of Zurich car-
diology. I had the privilege to work with several world
celebrities, such as Äke Senning, Paul Lichtlen and An-
dreas Grüntzig. My mentor in cardiology, Paul Lichtlen,
performed the first diagnostic coronary angiography, and
Äke Senning performed the first aortocoronary bypass op-
erations in Switzerland [2–5].
The Ospedale Civico experience (1972–1999)
At the end of 1971 I was nominated head of the department
of internal medicine at the Ospedale Civico, a medical di-
vision of 100 beds. With enthusiasm I started the reorgan-
isation of this department. It must be said that at that time
the hospitals in Ticino operated virtually on an “assisten-
tial” duty basis, without any technological support. I ex-
perienced the lack of modern equipment and knowledge-
able collaborators. Private funding allowed purchase of the
first advanced equipment. But it was in 1974 that, thanks to
a donation by Helmut Horten, a wonderful German bene-
factor, we opened the first angiographic and haemodynam-
ic laboratory in Ticino and performed the first coronary
angiographies and haemodynamic studies. Because of the
lack of a cardiac surgeon in Ticino, every 2–3 weeks we
discussed valvular and ischaemic patients who needed car-
diac surgery with Prof. Senning, referring them to the car-
diac surgery department in Zurich.
In the same period, we had the first four-bed intensive care
unit, which allowed us to use defibrillator and antiarrhyth-
mic therapy. At that time, treatment of acute myocardial
infarction was restricted to ECG monitoring, defibrillation,
anticoagulation and nitrates. We started to use an intra-aor-
tic balloon pump (IABP) in cases of cardiogenic shock [6].
We noticed that mortality after acute myocardial infarction
(AMI) immediately dropped from 30 to 15%.
The first Polaroid M-Mode echocardiography was essen-
tial in emergencies such as cardiac tamponade with peri-
cardiocentesis.
In 1974, we organised a cardiomobile to cover the territory.
For the first time, intensive-care nurses could reach pa-
tients at home, transport them under ECG monitoring and
defibrillate them when required [1] (fig. 2).
In 1978, with a young, determined and enthusiastic group
of nurses, we instituted the “Scuola di Infermiere di cure
intense”, which later became the institutional Cantonal
school.
In January 1989, we planned the first course at “la Scuola
di soccorritori professionali”. As mentioned, IABP was
one of our primary interests. We published our experience
with patients who underwent emergency coronary artery
bypass graft surgery in Zurich, transported from Ticino
across the Alps to Zurich by ambulance or helicopter under
IABP treatment [7]. In 1973, we implanted the first pace-
Figure 2: The first cardiomobile in Lugano and the Specialised Rescue School team.
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maker – a large single-chamber system with the generator
in the abdominal region. In the 1990 we implanted the first
smaller dual chamber pacemakers in the pectoral region [8,
9].
In the 1980s, under the leadership of Felix Gutzwiller, we
participated in three data collections in the epidemiologi-
cal MONICA Trial, focused on cardiovascular risk trends
in Switzerland, particularly in Canton Ticino [10, 11]. In
1975 I published several papers on coronary artery dis-
ease and cardiotoxic drugs; one of them – “Kardiotoxis-
che Medikamente unter besonderer Brücksichtigung der
Phoenothiazine und Imipraminderivate” – allowed me to
achieve the “Venia Legendi” at the University of Zurich
[12]. In the 1970s and 1980s, I had the privilege of teach-
ing every Friday to a group of students from Zurich Uni-
versity; some of them are nowadays Chiefs of various de-
partments.
In the same years I participated as national coordinator in
international multicentre trials [13]. In particular, we fo-
cused on the treatment of acute myocardial infarction with
fibrinolysis, in the GISSI and ISIS trials [14–17]. Relation-
ships with the GISSI and ISIS groups enabled us to be part
of a challenging research network. We also joined sever-
al groups such as CURE, HOPE and OASIS with Salim
Yusuf at Mc Master University of Hamilton, and TIMI Tri-
als with Eugene Braunwald. With these groups we had a
productive scientific collaboration.
In 1987, with Alessandro Del Bufalo I founded the
“Servizio Ricerca Cardiovascolare”, a centre dedicated to
multicentre randomised trials for innovative drugs. At that
time, we were very impressed by the results of ISIS 2,
which showed a decrease in mortality after AMI by more
than 50% with use of a combination of thrombolysis and
aspirin. After GISSI 1 and ISIS 2, we participated in a large
number of mega trials. Notably, we published several sci-
entific articles using the huge databases of these trials [13].
Among them I’d like to mention one focused on the behav-
iour of young patients with AMI in the GISSI 2 trial, pub-
lished in the Archives of Internal Medicine [18] and one on
the different outcomes of AMI based on gender, published
in The New England Journal of Medicine [19]. In that pro-
ductive period, we noticed that the combination of ECG
monitoring, thrombolysis and adjunctive therapies led to a
decrease in mortality after AMI of up to 8–9%.
Two Swiss cardiologists significantly changed the treat-
ment of coronary artery disease: Andreas Grüntzig and Ul-
rich Sigwart. Luckily, I had the privilege to work with
both of them in the 1960s in Zurich. In 1977, Grüntzig in-
troduced percutaneous transluminal coronary angioplasty
(PTCA) [20]; in 1988, Sigwart introduced the first stent
in Lausanne. This latter innovation enabled effective treat-
ment of one of the most life-threatening complications of
PTCA: coronary artery dissection.
Accordingly, we began to treat patient with acute coronary
syndrome (ACS) with PTCA and stent implantation, even
though we had no cardiac surgery unit on site. For potential
complications at that time, we had cross-border support
from the cardiac surgery unit of Varese [21].
Fondazione Cardiocentro Ticino (1999)
Finally, we arrive at the last chapter of my professional
life: the Cardiocentro Ticino Foundation era. Why the need
of a cardiac centre with cardiac surgery in Ticino? For too
many years I have witnessed of the suffering of hundreds
of patients and their families, who had to cross Gottardo’s
tunnel, often with language barriers, hoping for adequate
cardiac surgical treatment and a safe return back home.
Thanks to the donation of over 40 million Swiss francs by
my patient and friend Edward Zwick, a German physician,
I established this nonprofit centre with a cardiac surgery
department, despite strong opposition by many people in-
cluding colleagues. Politicians were sceptical about build-
ing a cardiological and cardiac surgery hospital in Ticino;
nevertheless, they gave permission, limiting the existence
of Cardiocentro as an independent institution to 25 years,
after which the Cardiocentro would be incorporated into
the Ente Ospedaliero Cantonale (a multisite institution cre-
ated in the 1980s). Cardiocentro was built in 16 months
and started its activities on July 1st, 1999 with the first
cardiac operation performed by Prof. Francesco Siclari –
chief of the cardiac surgery department – a key figure in
Cardiocentro. I promised to open the centre on this date
during my campaign for election as Gran Consiglio, repre-
sentative deputy of Lugano City. The requirement for ex-
cellent treatment of cardiovascular diseases was so urgent
and widespread that, in few years, the number of employ-
ees increased from 90 to nearly 400, including 42 cardiol-
ogists and 23 fellows. During this period I had the strong
support of Giovanni Pedrazzini, who shared with me this
dream. Our centre is an international community with 14
nationalities. Thanks to the significant drive of my collab-
orators, we developed a number of different fields of car-
diology.
Cardiac imaging
I am proud to say that this is one of the few worldwide in-
stitutions where all the three major imaging techniques be-
long to cardiology department: echocardiography, cardiac
CT and CMR. Echocardiography had impressive techno-
logical improvement, from the linear scanner in 1970 to 3D
echocardiography in 2010 [22]. Nowadays, echocardiogra-
phy is the most-used diagnostic tool after x-ray and ECG.
Transoesophageal echocardiography is essential in the op-
erating room and as a guide in all transcatheter percuta-
neous procedures [23] (fig. 3). CT scan is an indispensable
imaging tool to rule out coronary disease in individuals
with low-to-intermediate risk of coronary artery disease,
and is essential for planning transcutaneous aortic valve
implant (TAVI) or complex mitral valve repair. CMR in the
last two decades has become a crucial noninvasive imag-
ing modality in the cardiological workflow and it is a key
for precisely defining myocardial scarring and myocardial
perfusion, as well as right and left ventricular volumes and
function. Having these noninvasive imaging techniques
under a single direction (Dr F. F. Faletra) allows more cost-
effective use avoiding redundant or overlapping examina-
tions and correctly selecting the most effective technique
for individual patients. The cardiac imaging service has
published many papers in the most important journals and
several books.
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The radial lounge, the hydride room and intervention-
al cardiology
In 2015, Dr Marco Moccetti created our radial lounge for
patients treated via the radial approach, sometimes as out-
patients. In the last 5–6 years, use of the radial approach
has increased from 20 to 80%.
One of the most exciting interventions is MitraClip im-
plantation: we performed the first procedure in Switzerland
in early 2009. Currently, we are coordinating the Swiss Mi-
traClip register.
Another source of technological support is the hybrid room
– established in 2013 – where we perform structural car-
diac interventions and complex arrhythmic procedures
(3-chamber implantable cardioverter defibrillators, abla-
tions) and all combined interventions, with the surgical
team of Prof. Demertzis. Nowadays, using a new imaging
system which fuses together echocardiography and flu-
oroscopy (fusion imaging), we perform almost all tran-
scatheter percutaneous procedures for structural heart dis-
ease, including mitral and tricuspid clipping, mitral
surgical-like direct annuloplasty devices (Cardioband Ed-
wards Lifesciences, Irvine, CA, USA), occlusion of the left
atrial appendage, closure of paravalvular leaks, implanta-
tion of valve-in-valve and valve-in-native valves [24] (fig.
4).
International collaborations
I would like to focus on the importance of the international
collaboration network with academic centres in Europe,
USA and of course Switzerland, particularly with the Uni-
versity of Zurich, which was implemented thank to the
support of Prof. Thomas Lüscher. Since 2012 we are proud
to be associated with the University of Zurich and to be
a university centre; moreover, in February 2016 the FMH
recognised Cardiocentro as a class-A clinical institution
and training centre.
Treatment of STEMI
One of our priorities is to offer to all people in Canton Ti-
cino, a territory bordered by the Alps in the north and by
Italy in the South, the same opportunities to access high-
quality cardiological treatment regardless of whether they
live in peripheral valleys or more central towns. The ECG
transmission project involves the transmission of ECGs
from patients at home with acute coronary syndromes to
Cardiocentro cardiologists via i-phone, with rescue by am-
bulance or helicopter (REGA). In the case of ST elevation,
the secondary hospital will be by-passed. As a result, the
average time between pain onset and needle could be re-
duced to around 60 minutes (guidelines 90 minutes). In
these years we have performed more than 37 000 coronary
angiographies and more than 18 000 PCIs, offering to the
patients of the Canton suffering from STEMI a pain-to-
needle time of 60 minutes, with the lowest mortality in
Switzerland (3–4%).
Fondazione “Ticino Cuore”
Another Cardiocentro spin-off is the “Ticino Cuore” foun-
dation for resuscitation and defibrillation of patients with
sudden death in the territory. At present we have 1216
defibrillators distributed in the Canton and 84 376 people
(20.3% of the Ticino population) are able to resuscitate
with cardiac massage and defibrillation; more than 3000
are “first responders” after having being trained and cer-
tified in cardiac resuscitation. The collaboration with the
ambulance services for a prompt transfer to our catheter
laboratory for primary PCI and hypothermia managed in
our Intensive Care Unit (directed by Prof. Tiziano Cassina)
resulted in an increase in survival from 15% (the Swiss
average) to 50%. With the help of the University of Ap-
plied Sciences (SUPSI), an app to geo-localise the patient,
the nearest defibrillator and first responder has been devel-
oped, permitting a further decrease of mortality [25]. This
capillary organisation across the territory has given a gen-
eral sense of protection (fig. 5).
Figure 3: 3D imaging of different percutaneous procedures.
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Servizio Ricerca Cardiovascolare
Another activity of Cardiocentro I am proud of is the
“Servizio Ricerca Cardiovascolare”, active since 1987, and
currently employing 12 collaborators (all women) lead by
Dr. Elena Pasotti and Dr. Mariagrazia Rossi. We follow
up on many randomised clinical pharmacological and de-
vice trials in various research areas, with very skilled and
dedicated nurses. At the moment we are involved in 53
Figure 4: Interventional cardiology team.
Figure 5: Follow-up of outcome according to Utstein criteria.
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trials or registers (on-going and follow up), with more
than 1400 patients monitored yearly. A typical example in
which we were extensively involved was the evaluation
of new antithrombotic drugs, such as TRITON with pra-
sugrel, PLATO with ticagrelor and OASIS-7 with double-
dose clopidogrel. In all of these trials we have been a high
randomising centre. More recently, the new trials with an-
ti-PCSK9 antibodies resulting in a huge decrease in cho-
lesterol levels (FOURIER, ODYSSEY) and a significant
decrease of cardiovascular events.
Electrophysiology and Centre for Computational Med-
icine in Cardiology
In cardiac electrophysiology, the Cardiocentro team im-
plants a large number of pacemakers (~6000), ICDs, car-
diac resynchronisation devices (CRTs; ~1500). Angelo Au-
ricchio was the first electrophysiologist in the world to
implant the first wireless pacemaker. The electrophysiolo-
gy service has published many papers in the most impor-
tant journals and several books [26, 27]. One of the latest
spin-offs of Cardiocentro is the Centre for Computation-
al Medicine in Cardiology, where Prof. Angelo Auricchio
and Prof. Rolf Krause of US, are developing virtual cardiac
models using the ETH super computer in Lugano [28].
Translational cardiovascular medicine and SIRM
In the field of translational cardiovascular medicine, we
were the first in Switzerland to perform intracoronary in-
jection of bone marrow stem cells in 2004 [29]. This study
followed the protocol used in the REPAIR trial of Andreas
Zeiher’s group. In 2010, the Cardiocentro created the first
GMP cell factory approved by Swissmedic, which employ
seven collaborators. One important study in cellular ther-
apy is the Swiss AMI trial [30], for which we processed
stem cells for all involved institutions: the study compared
early vs late infusion of bone marrow stem cells after AMI,
with the randomisation of over 200 patients. Unfortunate-
ly, the results were not significant.
A further spin-off of Cardiocentro is the Foundation for
Cardiovascular Research and Education (FCRE), mostly
financed from Cardiocentro. To the question “which is the
best cell?” we developed the SIRM (Swiss Institute of Re-
generative Medicine) laboratory – located a few kilometres
from Cardiocentro – where Prof. Giuseppe Vassalli, Lu-
cio Barile and 43 collaborators work on regenerative med-
icine, in particular using exosomes that appears to provide
cardioprotection in animal models of AMI [31]. As the
only Swiss Centre, Cardiocentro and SIRM participate in
the European BAMI trial of stem cell therapy after acute
myocardial infarction, and in the international CHART-1
(Clinical Trial about Heart Failure Cardiopoietic Regener-
ative Therapy) [32].
In our project on the final stages of heart failure we occa-
sionally use ventricular assist devices (VADs) for destina-
tion therapy. One patient, unsuitable for heart transplanta-
tion, underwent VAD implantation in January 2011, thanks
to a donation by the Fidinam Foundation. Seven years after
the implantation, he still has an active lifestyle.
Meetings and humanitarian projects
Thanks to the active participation of our collaborators in
major international meetings, we are up-to-date on devices
and drug therapy, and, more importantly, we maintain hu-
man relationships with international colleagues to develop
the best treatment for our patients. We have also organised
several international meetings, nine MTE (“Meet The Ex-
pert”) with cardiac interventional live cases, five SCM
(“Stem Cell Meeting”) in regenerative medicine [33], and
some of the last TRM Forums (“Theo Rossi di Montelera”)
organised by Prof. Kappenberger on innovative electro-
physiology. Participants could consider a large number of
live cases involving PTCA, surgical interventions, mitral
valve implantations, TAVI and other interventions.
An important annual event is the Cavaliere del Cuore
meeting, at which cardiac arrest survivors are able to thank
those who helped them with resuscitation: a really emo-
tional moment.
We also collaborate in humanitarian projects for cardio-
pathic children with “Fondazione Bambini Cardiopatici
nel mondo”, founded in 1999. We participated in the
“SIRIA 2000 project”, a paediatric surgery institute in
Damascus, where, despite the war, the team could perform
337 cardiac interventions on children in 2017.
We were involved with the “Guinea Bissau project” in
which 22 compassionate interventions were performed in
Cardiocentro; for the future we will sponsor 50 cardiac
interventions on site every year at “Ospedale Cuomo” in
Dakar (Senegal). Some of our collaborators visit the hos-
pital in Guinea Bissau twice a year; a recent study showed
a prevalence of rheumatic valvular heart disease of 8% in
2441 children visited.
The current Cardiocentro situation
Finally, let me focus on the current Cardiocentro situation:
Will the institution remain a nonprofit foundation after
2020 or will it be incorporated into the public Ente Os-
pedaliero Cantonale? My only hope is that the quality of
Cardiocentro, developed over all these years, can be main-
tained.
Our future (fig. 6), to some extent already ongoing, has a
main focus on valvular interventions and, of course, per-
sonalised cardiology, genetics and new drugs. One of our
priorities is our participation in the new Medicine Mas-
ter in Biomedical Sciences of the Swiss Italian University
(USI) in Lugano, where Prof. Pedrazzini, my co-chief, is
the elected full professor of cardiology.
I cannot forget one special day, organised by myself and
Aldo Maggioni: a vision of the future of past projects,
discussed in 2016 by a group of friends in Cardiocentro,
with one World Heart Federation President (Salim Yusuf),
two European Society of Cardiology Presidents (Roberto
Ferrari and Barbara Casadei) and some legends in cardi-
ology (Mark Pfeffer, Rory Collins, Richard Peto, Gianni
Tognoni, Attilio Maseri and others). Recently a Separatum
in the European Hear Journal has been published with the
title “Lugano Perspectives” in cardiovascular diseases [12,
34].
To conclude, let me mention the “Mizar”, a building locat-
ed downtown in Lugano, which represents the new dream
of Cardiocentro Ticino in collaboration with the Munici-
pality of Lugano and the Swiss Italian University for basic
and translational research, an open bet.
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Figure 6: My dream: Lugano perspectives.
All of this long journey was possible thanks to the support
of all collaborators, and to the trust of the foundation coun-
cil and of the Administrative Direction of Cardiocentro.
But most of all I have to thank my parents, my wife Laura,
my three sons and my nine grandchildren. They have been
present not only in the happy moments of my life, but es-
pecially through the difficulties.
I want to close by quoting Darwin: “It is not the strongest
of the species that survives, nor the most intelligent, but the
one most responsive to the change.”
My particular thank goes to the Swiss Cardiology Society
for the Andreas Grüntzig Lecture. I am proud to accept this
honour for the Cardiocentro Ticino team and for the Ticino
population.
The literature references came from 525 publications (peer
and not peer reviewed papers) collected between 1996 and
October 2018.
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